A US district court judge scuttled Merck & Co. Inc.'s $2.5bn damages award against Gilead Sciences Inc., finding that Merck's patent related to hepatitis products is invalid for lack of enablement.
The decision is remarkable for eliminating a record-breaking verdict that Gilead's Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) infringes Merck's patent No....





